Table 5.

Stratification of Best response based on type of Immunotherapy (PR = Partial Response, CR = Complete Response, SD = Stable Disease, PD = Progressive Disease, ORR = Objective Response Rate, DCR = Disease Control Rate)

Anti-PD-1	No Metformin N = 20 (60.6%)	Metformin N = 14 (63.6%)
Best Response
PR	8 (40%)	7 (50%)	P = 0.6
CR	3 (15%)	3 (21.4%)
SD	2 (10%)	2 (14.3%)
PD	7 (35%)	2 (14.3%)
ORR	55%	71.4%	P = 0.33
DCR	65%	85.7%	P = 0.17
Median time to achieve best response (Months)	2.8	2.8	P = 0.28
Ipilimumab/Nivolumab	No Metformin N = 9 (27.3%)	Metformin N = 6 (27.3%)
Best Response
PR	6 (66.7%)	1 (16.7)	P = 0.16
CR	1 (11.1%)	2 (33.3%)
SD	0 (0%)	0 (0%)
PD	2 (22.2%)	3 (50%)
ORR	77.7%	50%	P = 0.26
DCR	77.7%	50%	P = 0.26
Median time to achieve best response (Months)	2.5	2.8	P = 0.9